A heart-on-chip is a microfluidic chip reproducing the mechanisms of a heart, in order to test medicine quickly and observe the reaction of heart cells. Great care is given to mimic the mechanics of a heart in an artificial structure, lined with live heart cells.
According to the World Health Organization, cardiovascular diseases are the leading cause of death worldwide [1]. In 2008, there were an estimated 17.3 million deaths due to cardiovascular diseases. This means that around 30% of the people who died in 2008 died because of a heart failure (Fig. 1). Moreover, cardiotoxicity is one of the leading causes of drug withdrawals.
Figure 1: From S. Mendis, P. Puska, B. Norrving, World Health Organization, World Heart Federation, and World Stroke Organization, Eds., Global atlas on cardiovascular disease prevention and control. Geneva: World Health Organization in collaboration with the World Heart Federation and the World Stroke Organization, 2011.
Animal models can help progress on the general understanding of the biological and physiological processes, but often fail to exactly represent human cardiotoxicity due to inter-species differences, explained Mathur & al. (2015) [2]. Indeed, the data obtained from animal testing is extrapolated for humans. The inaccuracies that result can become dangerous, especially when speaking of heart medication doses. There can also be substantial differences among humans due to age, race or genetic diversity. A heart-on-chip is a simple innovative way to reproduce cardiac tissue in three dimensions. The basic idea behind this microphysiological device is to find a simple and cheap method to apply for the study of cardiac diseases, for cardiac drug development and cardiotoxicity testing, for personalized medicine and for damaged heart tissue regeneration [3]. Zhang & al. (2017) [4] analyze the commercial progress of the major organ-on-chip technologies and predict a close integration in the pharmaceutical research space.
In order to create a valuable model, the microchip is supposed to mimic the heart’s main properties: the mechanical contractions, the molecular transport, the electrical activity and specific responses to some drug stimulation. It could also be interesting to add specific measurement systems, for potential recordings of contraction or action, or even calculation of tissue elastic modulus as done by Sidorov & al. [3]. First of all, the heart-on-chip should reproduce the cellular organization level in a living heart by exhibiting sarcomeres assembling with aligned tissue structure (Fig. 2) [5]. The heart is also one of the rare organs with active tissues that show intrinsic contractions. Moreover, the tissues are known to have a better cardiac differentiation when stimulated by a stretching pulse, as demonstrated by Zhuang & al. (2000) [6]. The contraction movement is therefore extremely important for a robust model with mature cardiomyocytes.
The heart is a pump but also a muscle, which means energy consumption and molecular transport. This aspect of the organ should be taken into consideration to model the nutrients supply and waste products elimination. Another key point to build a future automatic large scale method for the pharmaceutical industry is to obtain measurements data directly from the microchip to evaluate the potentiality of the tested therapeutic treatment. Indeed, integrating registration systems in the chip allows to avoid separating instruments, and therefore decreases the cost while increasing the precision [3]. It also allows for a better control of the stimulation. The professor Wikswo and his team just built an engineered 3D cardiac tissue: the I-Wire Heart-on-Chip incorporating wires that can be used for both electrical stimulation and chronic measures [3], [7].
In order to describe more precisely the general functioning of a heart-on-chip, this review will focus on the I-Wire Heart-on-chip created at Vanderbilt University [3]. They formed a PDMS casting mold and added it into a six-well plate (see Fig. 3) with a channel on each side for the insertion of titanium anchoring wires. An engineered 3D cardiac tissue (ECTC) was then cultured in this plate by Sidorov & al. [3] using ventricular cells from neonatal Sprague-Dawley rats, with fibrinogen and thrombin. As explained by Sidorov & al. [3], different types of cells are needed to generate proper cardiac tissue structure. Thus, they used cardiomyocytes as expected for a heart model but also cells specific from vessels and ECM (extracellular matrix) formation. For an easier culturing, the cells were placed in a culture medium (Gibco Fisher Scientific, DMEM). After 5-6 days of culture, cells begun to beat synchronously and within 13-15 days, muscular fibers were formed.
The contractions were detected and measured using an inverted optical microscope with a cantilever probe fixed on the condenser. It allows an optic measurement of the probe displacements and thus of the ECTC deformations. The ECTC is anchored on a motorized stage. Therefore, the Vanderbilt Institute could stimulate contraction by applying a controlled lateral force. The action potential is also measured by the use of a potassium chloride electrode and a silver chloride reference electrode. Moreover, the anchoring titanium wires were used for voltage stimulation.
More recent examples exist, such as the CISTEM project, in which Elveflow is a partner, to develop a heart-on-chip for personalized medicine.
Sidorov & al. were able to culture cardiomyocytes that differentiated into a beating cardiac muscle. They noticed an alignment of the myofibers between the two anchoring wires with the expected sarcomeres organization. As expected, the AP (action potential) amplitude observed was around 80–90 mV and the resting potential around 60–75 mV at a pacing rate of 2000 ms [3]. The professor Wikswo team also observed the Franck-Starling relationship when measuring the contractility of the ECTC in response of an applied horizontal force.
From Y. Sidorov, P. C. Samson, T. N. Sidorova, J. M. Davidson, C. C. Lim, and J. P. Wikswo, “I-Wire Heart-on-a-Chip I: Three-dimensional cardiac tissue constructs for physiology and pharmacology,” Acta Biomater., vol. 48, pp. 68–78, Jan. 2017. This video shows the I-Wire heart beating. It represents a heart fiber beating at different frequencies with the cantilever in black.
In a successful effort to assess the drug testing potentiality of the heart-on-chip, Sidorov & al [3] tried a β-adrenergic stimulation. In fact, adrenergic neurotransmitters are essential to regulate the heart rate. As expected, they noticed an increase of the measured force and the contraction velocity following the isoproterenol adding, known as adrenergic receptors activators. As for in vivo cardiomyocytes, the isoproterenol elicits a decrease of contraction duration. The I-Wire platform was also used in another study to reproduce these effects and build a mathematical Hill model based on a heart-on-chip [7]. However, it should be extended to humans for cardiac diseases study and even possibly for personalized medicine. Marsano & al. from the Basel University and Politechnico di Milano (2016) [8] built a 3D microtissue model with human induced pluripotent stem cells (hiPSC). They observed a better maturation of the human cardiomyocytes under cyclic mechanical stimulation. The heart-on-chip obtained, developed spontaneous and synchronous beating as well as the expected response of cardiomyocytes to isoprenaline, a β-adrenergic-agonist. It does not completely represent the cardiac muscle organization but still models the main cardiac tissue properties.
Research demonstrated that the heart-on-chip technology has the potentiality for pharmacologic and research applications especially when using integrated registration systems for contraction and action potential. Indeed, the first microchip device described can apply a transversal force with its cantilever probe and directly measure the responses of the ECTC. The wires are glued in the PDMS mold. They stay during the whole cell culture and for the measurements during the analysis phase. This measurement technique is simpler, more accurate but also decreases the cost compared to classical measurement devices. Having a reliable heart-on-chip opens the door for a human-on-chip: a multi-organ microdevice. It is essential for drug testing to assess not only the cardiotoxicity but also the global inter-organs interactions.
Authors: Marjorie Metzger, Julie Cavallasca and Guilhem Velvé Casquillas
With the support of the MSCA-RISE CISTEM project Grant agreement number: 778354
Written by Marjorie Metzger, revised by Julie Cavallasca, under the supervision of Dr. Guilhem Velve Casquillas
Email* I hereby agree than Elveflow uses my personal data
Do you want tips on how to best set up your microfluidic experiment? Do you need inspiration or a different angle to take on your specific problem? Well, we probably have an application note just for you, feel free to check them out!
Lab-On-a-Chip drug testing in Microfluidics
Exploring Organ-on-a-Chip Technology: A comprehensive review
Coronavirus (SARS-CoV2) diagnostic through microfluidics
In this report, we identify the following two main purposes for the 3D cell market
At the beginning of the third millennium, due to prolonged aging, neurodevelopmental disorders are growing and a much deeper understanding of the brain is necessary.
The liver is involved in more than 300 vital functions, but is mainly known for being part of the digestive tract, where it has the extremely important role of metabolizing both xenobiotics and nutrients (carbohydrates and lipids).
While many animal models have been used to study lung diseases, they lack sufficient similarity with human systems, leaving gaps in what is possible in animal-based platforms.
It could be extremely interesting to build a human-on-chip that will model the interactions between different organs, but it is also essential to develop simulations of tissue-tissue interfaces and more generally of local organ behavior.
Multi-organs on chip could also allow us to witness the side effects of certain drugs on different organs, not limited to those that the treatment targets.
Since 2012, more and more people, companies or lab, have worked on the organ-on-a-chip. These cell cultures can, thanks to microfluidics, mimic the cells microenvironment of the human body. Thus, these chips could become wonderful search accelerators and we can hope that, in ten years, they could replace the animal testing. Finally, organs on chips could lead us to personalized medicine.
Cell culture consists in growing cells in an artificial environment in order to study their behavior in response to their environment[1]. Different kinds of cell cultures can be found nowadays, and some would be more suited than others depending on its properties and applications.
Organ-on-chip companies developping innovative technologies
Although we take part in various research projects such as artificial photosynthesis, pathogen detection and stem cell differentiation, the ultimate goal of our entrepreneurial adventure is to accelerate anti-aging research.
Get a quote
Name*
Email*
Message
Newsletter subscription
We will answer within 24 hours
By filling in your info you accept that we use your data.
Collaborations
Need customer support?
Serial Number of your product
Support Type AdviceHardware SupportSoftware Support
Subject*
I hereby agree that Elveflow uses my personal data Newsletter subscription
How can we help you?
Message I hereby agree that Elveflow uses my personal data Newsletter subscription